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Abstract 0 Two poly(ethylene glycol) (PEG)-peptides were synthe-
sized and tested for their ability to bind to plasmid DNA and form
soluble DNA condensates with reduced spontaneous gene expression.
PEG-vinyl sulfone or PEG-orthopyridyl disulfide were reacted with the
sulfhydryl of Cys-Trp-Lys18 (CWK18) resulting in the formation of
nonreducible (PEG-VS-CWK18) and reducible (PEG-SS-CWK18) PEG-
peptides. Both PEG-peptides were prepared on a micromole scale,
purified by RP-HPLC in >80% yield, and characterized by 1H NMR
and MALDI-TOF. PEG-peptides bound to plasmid DNA with an
apparent affinity that was equivalent to alkylated (Alk)CWK18, resulting
in DNA condensates with a mean diameter of 80−90 nm and ú (zeta)
potential of +10 mV. The particle size of PEG-peptide DNA
condensates was constant throughout the DNA concentration range
of 0.05−2 mg/mL, indicating these to be approximately 20-fold more
soluble than AlkCWK18 DNA condensates. The spontaneous gene
transfer to HepG2 cells mediated by PEG-VS-CWK18 DNA conden-
sates was over two orders of magnitude lower than PEG-SS-CWK18
DNA condensates and three orders of magnitude lower than AlkCWK18
DNA condensates. PEG-VS-CWK18 efficiently blocked in vitro gene
transfer by reducing cell uptake. The results indicate that a high loading
density of PEG on DNA is necessary to achieve highly soluble DNA
condensates that reduce spontaneous in vitro gene transfer by blocking
nonspecific uptake by HepG2 cells. These two properties are important
for developing targeted gene delivery systems to be used in vivo.
Introduction
A variety of macromolecules including cationic lipids,1
polylysine,2 polyethylenimine,3 and dendrimers4 have been
used as carriers to bind to negatively charged plasmid DNA
and facilitate spontaneous gene transfer in cell culture as
a result of charge interaction between the DNA carrier
complex and the cell surface. Unfortunately, the perfor-
mance of these nonviral gene delivery carriers are far less
efficient in vivo due in part to the rapid pharmacokinetics
and clearance of DNA complexes.5,6 This relates to both
the particle size and surface charge of the delivery system.7
For example, cationic lipids form large DNA complexes that
are trapped in the capillary beds of the lung5 whereas
smaller (<100 nm) peptide DNA condensates are scavenged
by mononuclear phagocytic system (MPS) cells of the liver,6
limiting the development of DNA delivery systems that
target peripheral tissues.
The intravenous dosing of most colloids leads to op-
sonization and MPS cell uptake in the lung, liver, and
spleen.8 In the case of liposomes, this limitation has been
largely overcome by simultaneously reducing the particle
size to <100 nm and modifying the surface with PEG9 since
this polymer possesses the ideal hydration and flexibility
to create a steric layer that allows liposomes to avoid
opsonization and detection by MPS cells.10
Several studies have described the synthesis of PEG-
containing polymers designed to create a steric layer on
the surface of DNA condensates,7,11-17 with the aim of
improving their solubility and in vivo performance. An
early study by Wolfert et al. described the synthesis of
grafted copolymers of PEG (5 or 12 kDa) and polylysine100
prepared by carbodiimide coupling 5-10 mol % of succi-
nylated-PEG onto the side chains of polylysine.11,12 The
resulting PEG-peptides were less toxic to cells in culture
compared to polylysine100, formed DNA condensates pos-
sessing a reduced effective surface charge, and had slightly
improved solubility over control polylysine DNA conden-
sates but surprisingly were unable to reduce spontaneous
gene transfer in HepG2 cells12 in vitro, suggesting that they
would not be able to block nonspecific interactions with
cells in vivo.
Subsequently, Choi et al. derivatized the side chains of
polylysine120 with 5-25 mol % low molecular weight PEG
of 550 Da.13 The resulting PEG-peptide DNA condensates
were also less toxic to cells than polylysine120 DNA con-
densates but were similar to Wolfert’s PEG-peptides in
their inability to reduce spontaneous gene transfer in
HepG2 cells, indicating that low molecular weight PEG was
no more effective than high molecular weight PEG. Using
a similar approach, PEG polylysine dendrimer copolymers
were recently reported by the same group and used to form
DNA condensates that were more nuclease resistant than
polylysine DNA condensates but which were not examined
for gene transfer.14
In addition, Katayose et al. synthesized PEG-polylysine
block copolymers to incorporate 5 kDa PEG into polylysine
by random polymerization of N-carboxyanhydride ε-(ben-
zyloxycarbonyl)-lysine with amino-PEG, resulting in a
polymer with a lysine to PEG ratio of approximately 18:
115,16 representing approximately 5 mol % PEG. These
PEG-polylysine DNA condensates were also reportedly
much more resistant to endonuclease than uncondensed
DNA but were not examined for solubility or gene trans-
fer.16,17
To date, there are no reports of a PEG-peptide DNA
condensing agents that significantly increase the solubility
of the DNA condensates and/or reduce spontaneous gene
transfer to HepG2 cells. These are both significant prob-
lems since the poor solubility of peptide DNA condensates
of approximately 50-100 µg/mL limits the dosing volume
and precludes dose escalation during in vivo gene transfer.
Likewise, reducing the level of spontaneous gene transfer
in vitro is a first step toward developing DNA formulations
that avoid nonspecific gene transfer to cells in vivo and may
allow the development of DNA formulations that target to
peripheral sites. Here we describe the synthesis and
formulation properties of two PEG-peptides, both of which
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significantly improve DNA condensate solubility and one
of which dramatically reduces spontaneous gene transfer
of DNA condensates in vitro. The results suggest that these
two properties are closely linked to the loading level of PEG
on peptide DNA condensates.
Materials and Methods
PEG-orthopyridyl disulfide (PEG-OPSS, 5 kDa) and PEG-vinyl
sulfone (PEG-VS, 5 kDa) were purchased from Shearwater Inc.
(Huntsville, AL) and Fluka (Ronkonkoma, NY), respectively. Fetal
calf serum and LipofectAce were obtained from Gibco BRL
(Gaithersburg, MD). Minimum essential media (MEM) and CM
Sephadex C50 were purchased from Sigma (St. Louis, MO). TCEP
(tris(2-carboxyethyl)phosphine hydrochloride) was purchased from
Aldrich, (Milwaukee, WI). D-Luciferin and luciferase from Photinus
pyralis were from Boehringer Mannheim (Indianapolis, IN). The
5.6 kb plasmid (pCMVL) encoding the reporter gene luciferase
under the control of the cytomegalovirus promoter was a gift from
Dr. M. A. Hickman at the University of California, Davis.18
pCMVL was produced in E. coli and purified using a Qiagen
Ultrapure-100 kit (Santa Clarita, CA). Bradford reagent was
purchased from Bio-Rad (Hercules, CA). Preparative and analyti-
cal C18 reverse phase HPLC columns were purchased from Vydac
(Hesperia, CA). HPLC was performed using a computer-interfaced
HPLC and fraction collector from ISCO (Lincoln, NE).
Synthesis of PEG-VS-CWK18 and PEG-SS-CWK18sCWK18
(Cys-Trp-Lys18) and dimeric-CWK18 were synthesized and char-
acterized as described previously.19 The Cys residue on CWK18
was alkylated with iodoacetic acid resulting in AlkCWK18 as
reported.19 The synthesis of PEG-VS-CWK18 utilized dimeric-
CWK18 (0.5 µmol) which was reduced to form 1 µmol of CWK18 by
reaction with 25 µmol of TCEP20 in 0.5 mL of 0.1 M sodium
phosphate pH 7 for 4 h at room temperature. PEG-VS-CWK18 was
formed by reacting 1 µmol of reduced CWK18 with 30 µmol of PEG-
VS in a total volume of 1.2 mL of 0.1 M sodium phosphate pH 7
at room temperature for 12 h. The progress of the reaction was
monitored by analytical RP-HPLC eluted at 1 mL/min with 0.1%
TFA and a gradient of acetonitrile (5-65% over 30 min) while
detecting by A280nm. The reaction mixture was applied to a CM
Sephadex C50 cation-exchange column (0.7 × 15 cm) eluted with
60 mL of water to remove free PEG-VS as the unbound fraction
and then with 15 mL of 1.5 M sodium chloride while collecting 5
mL fractions. PEG-VS-CWK18 and CWK18 were detected by A280nm
and were pooled and desalted by 5 h dialysis against 4 L of water
in 1000 MWCO tubing and then freeze-dried. PEG-VS-CWK18 was
resolved from CWK18 by injecting 0.5 µmol onto a semipreparative
C18 RP-HPLC column (2 × 25 cm) eluted at 10 mL/min with 0.1%
TFA and a gradient of acetonitrile (5 to 65% over 30 min) while
detecting by A280nm. The peak eluting at 25 min yielded 0.8 µmol
of PEG-VS-CWK18 (80%) based on tryptophan absorbance (ε280nm
) 5600 M-1 cm-1).
A disulfide bond exchange reaction was used to prepare PEG-
SS-CWK18. Prior to conjugation of PEG-OPSS, dimeric-CWK18 was
reduced and then purified by RP-HPLC eluted as described above.
Reduced CWK18 (1 µmol) was reacted with 4 µmols of PEG-OPSS
in 1 mL of 0.1 M sodium phosphate pH 7 at room temperature for
30 min. The reaction was monitored by analytical RP-HPLC which
detected a single new product peak eluting at 25 min. PEG-SS-
CWK18 was purified by injecting 0.5 µmol portions onto semi-
preparative RP-HPLC eluted as described above resulting in an
isolated yield of 95%.
PEG-VS-CWK18 and PEG-SS-CWK18 (1 µmol) were prepared
for 1H NMR by D2O exchange followed by dissolving the sample
in 0.5 mL of D2O (99.96%) containing acetone as an internal
standard. 1H NMR spectra were generated on a Bruker 500 MHz
spectrometer operated at 23 °C. PEG-peptides were prepared for
MALDI-TOF by dissolving 5 nmol in 20 µL of water. These (0.5
µL) were combined with 0.5 µL of saturated R-cyano-4-hydroxy-
cinnamic acid in 50 v/v % acetonitrile and 0.3% trifluoroacetic acid
and then analyzed on a Vestec LaserTec MS (PerSeptive Biosys-
tems, Framingham, MA) operated in the linear mode at 20 kV.
Formulation of Peptide DNA CondensatessPeptide DNA
condensates were formed by adding 75 µg of DNA (pCMVL in 750
µL of 5 mM Hepes pH 7.4) to varying amounts of peptide (7.5 to
90 nmol in 750 µL of Hepes) while vortexing, followed by
equilibration at room temperature for 1 h. Peptide binding to DNA
was monitored by a fluorescent dye displacement assay.19 A 1 µg
aliquot of the peptide DNA condensate was diluted to 1 mL in
Hepes containing 0.1 µM thiazole orange. The fluorescence of the
intercalated dye was measured on an LS50B fluorometer (Perkin-
Elmer, UK) in a microcuvette by exciting at 500 nm while
monitoring emission at 530 nm.
The particle size of peptide DNA condensates were analyzed at
a DNA concentration of 50 µg/mL in Hepes by quasielastic light
scattering (QELS). The particle surface charge was determined
by ú (zeta) potential analysis using a Brookhaven ZetaPlus
(Brookhaven Instruments). The solubility of peptide DNA con-
densates were determined by measuring particle size as a function
of DNA concentration (50 µg/mL to 2 mg/mL) at a constant peptide:
DNA stoichiometry of 0.4 nmol of peptide per µg of DNA corre-
sponding to a charge ratio (NH4+:PO4-) of 2.3:1.
DNA cocondensates were prepared by add-mixing AlkCWK18
and PEG-VS-CWK18 in ratios ranging from 0 to 100 mol % and
condensing DNA at a charge ratio of 2.3:1 as described above. To
establish the mol ratio of peptides bound to DNA, condensates
were dialyzed in a fixed volume (0.5 mL) dialyzer for 75 h against
water using a 100 000 MWCO membrane. Peptide DNA conden-
sates in the retentate (0.5 mL) were dissociated by adding 50 µL
of 5 M sodium chloride in 0.1% TFA. AlkCWK18 and PEG-VS-
CWK18 were quantified by injecting 1 nmol of peptide (100 µL)
onto analytical RP-HPLC eluted with 0.1% TFA and a gradient
of acetonitrile (5 to 65% over 30 min) while detecting tryptophan
by fluorescence (λex280nm, λem350nm). The peak integration areas were
used to quantify AlkCWK18 and PEG-VS-CWK18 with reference
to standard curves developed for each peptide.
In Vitro Gene Expression and Cell BindingsHepG2 cells
were plated at 1.5 × 105 cells per 35 mm well and grown to 40-
70% confluence in MEM supplemented with 10% fetal calf serum
(FCS). Peptide DNA condensates (10 µg of DNA) were added
dropwise to triplicate sets of cells in 2% FCS containing 80 µM
chloroquine. After 5 h incubation at 37 °C, the media was replaced
with MEM supplemented with 10% FCS, and luciferase expression
was determined at 24 h. Cells were washed twice with ice-cold
phosphate-buffered saline (calcium and magnesium free) and then
treated with 0.5 mL of ice-cold lysis buffer (25 mM Tris hydro-
chloride pH 7.8, 1 mM EDTA, 8 mM magnesium chloride, 1%
Triton X-100, 1 mM DTT) for 10 min. The cell lysate was scraped,
transferred to 1.5 mL microcentrifuge tubes, and centrifuged for
7 min at 13 000g at 4 °C to pellet debris. Lysis buffer (300 µL),
sodium-ATP (4 µL of a 180 mM solution, pH 7, 4 °C), and cell lysate
(100 µL, 4 °C) were combined in a test tube, briefly mixed, and
immediately placed in the luminometer. Luciferase relative light
units (RLU) were recorded on a Lumat LB 9501 (Berthold
Systems, Germany) with 10 s integration after automatic injection
of 100 µL of 0.5 mM D-luciferin (prepared fresh in lysis buffer
without DTT). The expression level of luciferase was normalized
for protein using the Bradford assay,21 and the relative light units
were converted to fmol of luciferase/mg of protein using a standard
curve developed by adding luciferase to cell supernatant. Each
experimental result represents the mean and standard deviation
derived from a triplicate set of transfections.
LipofectAce (Gibco BRL, 1:2.5 w/w dimethyl dioctadecylammo-
nium bromide and dioleoylphosphatidylethanolamine) was opti-
mized for use to mediate gene transfection in HepG2 cells
according to the manufacturer’s instructions. DNA/LipofectAce
complexes were prepared by combining 10 µg of DNA in 100 µL of
serum free media (SFM) with 60 µL of LipofectAce prepared in
150 µL of SFM. The LipofectAce DNA complex was then diluted
with 1.7 mL of SFM and used to transfect HepG2 cells for 5 h
followed by replacement of the transfecting media with MEM
supplemented with 10% FBS. The cells were incubated for a total
of 24 h, harvested, and then analyzed for luciferase as described
above.
Iodinated plasmid DNA was prepared with specific activity of
300 nCi per µg of DNA as described previously.22 Prior to forming
DNA condensates, the specific activity of the 125I DNA was
adjusted to 4.5 nCi per µg of DNA by combining with unlabeled
plasmid. DNA condensates were prepared using AlkCWK18, PEG-
SS-CWK18, or PEG-VS-CWK18 as described above. Peptide 125I-
DNA condensates (10 µg) were used to transfect HepG2 cells for
5 h according to the procedure described above. The radioactive
media was removed, cells were washed with phosphate-buffered
saline, harvested with lysis buffer, and the cell-associated radio-
activity was quantified by gamma counting.
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Results
PEG-Peptide SynthesissPEG was covalently attached
to the Cys residue of a 20 amino acid synthetic peptide
(CWK18) to prepare two PEG-peptides possessing either a
reversible (PEG-SS-CWK18) or irreversible (PEG-VS-
CWK18) covalent linkage (Figure 1). Each reaction was
optimized by systematically changing the pH and the
stoichiometry of peptide to PEG while monitoring the
product formation by analytical RP-HPLC. Since the reac-
tion of CWK18 with PEG-VS at pH 7 was slow (12 h), TCEP
was added to reduce dimeric-CWK18 and also inhibit its
re-formation during conjugation with PEG-VS. At pH 7, a
mol ratio of PEG-VS:CWK18 of 30:1 resulted in optimal
conjugation to form PEG-VS-CWK18. At suboptimal stoi-
chiometries or lower pH the reaction was incomplete
whereas at a higher pH, dimeric-CWK18 re-formed as the
major product.
In contrast to the synthesis of PEG-VS-CWK18, the
optimal reaction conditions to prepare PEG-SS-CWK18 only
required a 4 mol excess of PEG-OPSS over CWK18 at pH
7. In this case, attempts to block the formation of dimeric-
CWK18 with TCEP led to the reduction of PEG-OPSS,
completely inhibiting the desired reaction. Instead, reduced
CWK18 was prepared and found to react rapidly (30 min)
with PEG-OPSS with minimal formation of dimeric-CWK18.
RP-HPLC analysis of the crude reaction product of PEG-
VS-CWK18 demonstrated a nearly complete disappearance
of CWK18 with the formation of a new peak eluting at 25
min (Figure 2B). Despite the apparent complete resolution
of the desired product, careful examination revealed that
PEG-VS coeluted with PEG-VS-CWK18. This was evident
from NMR analysis which determined a 10-fold excess of
PEG relative to CWK18 in the HPLC purified product (data
not shown). Consequently, PEG-VS-CWK18 was purified
using cation exchange to remove excess PEG-VS and then
by RP-HPLC to remove unreacted CWK18 resulting in a
product that rechromatographed as a single peak on RP-
HPLC (Figure 2D). Proton NMR analysis identified reso-
nances assigned to the R, â, γ, δ, and ε protons of the Lys
residues as well as the Trp aromatic resonances (Figure
3A). Integration of protons at 3.67 ppm (PEG) relative to
the signal at 2.97 ppm (Lys ε) produced a peak area ratio
of 13.5:1 corresponding to a 1:1 conjugate of PEG122 and
CWK18.
RP-HPLC analysis of the crude reaction product of PEG-
OPSS and CWK18 identified a product peak eluting at 25
min, a PEG-OPSS reagent peak at 28 min, a thiol pyridine
(TP) byproduct peak at 5 min, and a trace of dimeric-CWK18
eluting at 15 min (Figure 2C). PEG-SS-CWK18 was isolated
in a single step by semipreparative RP-HPLC, rechromato-
graphed as a single peak on analytical HPLC (Figure 2E),
and produced an NMR spectrum with an integration ratio
of PEG:Lys also establishing a 1:1 conjugate of PEG123 and
CWK18 (Figure 3B).
MALDI-TOF analysis of PEG-VS-CWK18 and PEG-SS-
CWK18 produced a broad peak centered at 8433 and 8297
Figure 1sReaction schemes for the synthesis of PEG-CWK18 conjugates. (A) TCEP was used to reduce dimeric-CWK18 to generate CWK18. This was reacted
in situ with PEG-VS to form PEG-VS-CWK18. (B) Alternatively, the reaction of CWK18 with PEG-OPSS formed PEG-SS-CWK18. (C) AlkCWK18 was produced by
reacting CWK18 with iodoacetic acid. The R, â, γ, δ, and ε protons of Lys of PEG-SS-CWK18 illustrate the nomenclature used for assigning PEG-peptides in
Figure 3.
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m/z, respectively. These results were consistent with the
formation of conjugates of CWK18 (2648 amu) and polydis-
perse PEG of approximately 5800 Da.
PEG-Peptide DNA Condensate FormulationsThe
DNA binding affinity of AlkCWK18, PEG-VS-CWK18, and
PEG-SS-CWK18 were compared using a fluorescent dye
displacement assay. A coincident titration curve for each
peptide with an asymptote at 0.3 nmol per µg of DNA
corresponding to a charge ratio of 1.8:1 suggested that both
PEG-peptides bind to DNA with equivalent affinity as
AlkCWK18 (Figure 4).
The particle size and ú potential of DNA condensates
prepared with AlkCWK18, PEG-VS-CWK18, and PEG-SS-
CWK18 were examined as a function of peptide:DNA
stoichiometry (Figure 5). The mean diameter for both PEG-
peptide DNA condensates was 90 nm at a charge ratio of
1.8:1 or higher whereas the mean diameter for AlkCWK18
Figure 2sAnalytical RP-HPLC analysis of PEG-CWK18 conjugates. The
reaction of dimeric-CWK18 with TCEP and PEG-VS formed a single major
product as shown in panel B. Alternatively, reduced CWK18 (panel A) reacted
with PEG-OPSS to produce PEG-SS-CWK18, dimeric-CWK18, thiol-pyridine
(TP), and unreacted PEG-OPSS as shown in panel C. Purified PEG-VS-
CWK18 and PEG-SS-CWK18 both eluted as a single peak as shown in panels
D and E, respectively.
Figure 3s1H NMR analysis of PEG-CWK18 conjugates. The 500 MHz 1H
NMR spectrum of PEG-VS-CWK18 (panel A) and PEG-SS-CWK18 (panel B)
are illustrated with the key signals of the Lys, Trp and PEG identified according
to Figure 1. The integration of the ε protons of Lys relative to the PEG protons
established a degree of polymerization of 122 for PEG-VS-CWK18 and 123
for PEG-SS-CWK18.
Figure 4sRelative binding affinity of PEG-CWK18 conjugates to DNA. The
fluorescence intensity resulting from the titration of AlkCWK18 (b), PEG-SS-
CWK18 (9), and PEG-VS-CWK18 (2) to compete for intercalator dye binding
to DNA is shown. An asymptote at 0.3 nmol of each peptide per µg of DNA
established that each peptide binds to DNA with equivalent affinity.
Figure 5sQELS particle size and ú potential analysis of PEG-CWK18 DNA
condensates. The mean particle size of AlkCWK18 (b), PEG-SS-CWK18 (9),
and PEG-VS-CWK18 (2) DNA condensates is plotted as a function of peptide:
DNA stoichiometry in panel A. The mean ú potential for each DNA condensate
is plotted in panel B. An indistinguishable particle size and ú potential was
determined for each PEG-CWK18 conjugate. However, a significant decrease
in the ú potential for PEG-CWK18 DNA condensates (+10 mV) versus
AlkCWK18 DNA condensates (+35 mV) provided evidence of the formation of
a steric barrier.
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DNA condensates was 60 nm (Figure 5A). In contrast, a
large decrease in ú potential of +25 mV was identified for
PEG-peptide DNA condensates at a charge ratio of 1.8:1
compared to AlkCWK18 DNA condensates (Figure 5B).
Since PEG-VS-CWK18 and AlkCWK18 possess equivalent
DNA binding affinity, add-mixtures of the two peptides
were used to prepare DNA cocondensates. The average
particle size increased from 65 to 80 nm using add-mixtures
of AlkCWK18 and PEG-VS-CWK18 varying from 0 to 100
mol % while keeping the charge ratio constant at 2.3:1
(Figure 6A). Likewise, the ú potential decreased from +35
mV to +10 mV as the stoichiometry of PEG-VS-CWK18
increased (Figure 6B), suggesting the formation of DNA
cocondensates with intermediate PEG loading.
To further confirm the formation of DNA cocondensates,
unbound peptides were removed by microdialysis and the
ratio of peptides bound to DNA was determined by HPLC.
Control experiments established the nearly complete re-
moval (>90%) of free AlkCWK18 or PEG-VS-CWK18 from
the retentate after 75 h of dialysis (Figure 7A). However,
the dialysis of DNA cocondensates prepared at charge
ratios of 2.3:1 resulted in the removal of unbound peptide
and retention of >35% of the tryptophan fluorescence.
Dissociation and RP-HPLC analysis of the retained peptide
(Figure 7B-F) allowed recovery of AlkCWK18 and PEG-
VS-CWK18 at ratios that agreed to within 16% of the input
ratio for each DNA cocondensate (Table 1) in which the
loss of PEG-VS-CWK18 was greater than that of AlkCWK18.
DNA condensate solubility was evaluated by examining
the particle size of concentrated solutions. AlkCWK18 DNA
condensates increased in particle size from 60 to 400 nm
when increasing DNA concentration from 50 to 500 µg/mL
and then formed visible flocculates at higher concentra-
tions. Alternatively, PEG-VS-CWK18 DNA condensates
maintained a mean diameter of <100 nm throughout
concentrations ranging from 0.05 to 2 mg/mL and showed
no sign of increasing in size (Figure 8). Likewise, substitu-
tion of PEG-SS-CWK18 for PEG-VS-CWK18 resulted in the
formation of DNA condensates with 88 nm mean diameter
at 2 mg/mL.
Figure 6sQELS particle size and ú potential analysis of peptide DNA
cocondensates. Particle size analysis was used to characterize peptide DNA
cocondensates prepared at 50 µg/mL of DNA and varying mol % of AlkCWK18
and PEG-VS-CWK18 as shown in panel A. The ú potential of DNA
cocondensates is shown in panel B. The mean particle size changes from 65
to 80 nm whereas the ú potential of DNA cocondensates decreases from
+35 to +10 mV with increasing mol % of PEG-VS-CWK18.
Figure 7sRP-HPLC analysis of peptide DNA cocondensates. The time course
of dialysis of free AlkCWK18 (b), free PEG-VS-CWK18 (9), AlkCWK18 DNA
condensates (1), PEG-VS-CWK18 DNA (2), and cocondensates of 25:75 ([),
50:50 (O), 75:25 ()) mol % of AlkCWK18:PEG-VS-CWK18 bound to DNA was
determined by tryptophan fluorescence of the retentate (panel A). After 75 h
of dialysis, peptide DNA condensates in the retentate were dissociated with
sodium chloride and directly chromatographed on RP-HPLC. Panels B−F
illustrate chromatograms resulting from 100 mol % PEG-VS-CWK18 DNA
condensates (panel B), DNA cocondensates prepared with 75:25 (panel C),
50:50 (panel D), 25:75 (panel E) PEG-VS-CWK18:AlkCWK18, and 100 mol %
AlkCWK18 DNA condensates (panel F).












a Based on HPLC standard curves developed for AlkCWK18 and PEG-VS-
CWK18.
Figure 8sSolubility of peptide DNA condensates. Particle size analysis was
performed as a function of DNA concentration using 100 mol % AlkCWK18
(b) and 100 mol % PEG-VS-CWK18 (2) DNA condensates and using
AlkCWK18:PEG-VS-CWK18 DNA cocondensates prepared with 50 ([) and
90 (9) mol % PEG-VS-CWK18. The particle size increased to >400 nm above
500 µg/mL for AlkCWK18 DNA condensates but remained at <100 nm for
PEG-VS-CWK18 DNA condensates throughout concentrations up to 2 mg/
mL.
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DNA cocondensates containing 50 mol % PEG-VS-CWK18
and AlkCWK18 possessed similar poor solubility properties
to that of 100 mol % AlkCWK18 DNA condensates. How-
ever, DNA cocondensates composed of 90 mol % PEG-VS-
CWK18 and 10 mol % AlkCWK18 also maintained a particle
size of <100 nm up to 750 µg/mL and then formed larger
particles (>100 nm) at DNA concentrations of 1 mg/mL or
higher (Figure 8).
DNA condensates prepared with PEG-VS-CWK18, PEG-
SS-CWK18, AlkCWK18, and add-mixtures of AlkCWK18 and
PEG-peptides were compared by measuring luciferase
expression in HepG2 cells 24 h post-transfection (Figure
9). PEG-VS-CWK18 DNA condensates reduced spontaneous
gene transfer by three orders of magnitude compared to
AlkCWK18 DNA condensates. The reduction was only 10-
fold when transfecting with DNA cocondensates prepared
with 50 mol % PEG-VS-CWK18 and only 2-fold using
cocondensates composed of 25 mol % PEG-VS-CWK18
(Figure 9).
The gene transfer properties of PEG-SS-CWK18 DNA
condensates were significantly different than PEG-VS-
CWK18 DNA condensates. DNA condensates prepared with
100 or 75 mol % PEG-SS-CWK18 reduced spontaneous gene
transfer by 5-fold relative to AlkCWK18 DNA condensates
while DNA cocondensates prepared with 50 or 25 mol %
of PEG-SS-CWK18 were equivalent to AlkCWK18 DNA
condensates (Figure 9).
The cell binding of 125I-DNA was compared for AlkCWK18,
PEG-VS-CWK18, and PEG-SS-CWK18 DNA condensates
during a 5 h transfection. Approximately 14% of the
radioactivity was cell-associated for AlkCWK18 DNA con-
densates whereas only 6.8% and 0.2% were cell-associated
when using PEG-SS-CWK18 and PEG-VS-CWK18 as DNA
condensing agents, respectively (Figure 10). These results
correlated well with the observed gene transfer efficiency
for each peptide DNA condensate, suggesting differences
in the uptake of these condensates was the main cause of
their difference in gene expression.
Discussion
The targeting of DNA to specific cells in vivo for the
purpose of mediating therapeutically relevant levels of gene
expression will require systematic optimization of the drug
delivery system.23 The design of such delivery systems must
attempt to minimize the carrier’s toxicity and antigenicity,
increase the DNA’s metabolic stability, control the particle
size and charge, and increase the DNA condensate solubil-
ity as well as provide a means to target DNA to the nucleus
of the cell. Thus far, PEG-peptides have been reported to
decrease toxicity,11-13 increase DNA stability,14,17 and
improve DNA solubility.12 In the present study we report
the synthesis of two PEG-peptides that simultaneously
create very soluble DNA condensates and significantly
inhibit spontaneous gene transfer of peptide DNA conden-
sates in vitro. A major finding is that both of these
properties are influenced to different degrees by the load
level of PEG on DNA condensates.
The directed synthesis of the low molecular weight PEG-
peptides reported here is a major distinction of this work
compared to others. The conjugation of PEG (5000 Da) to
a single cysteine of CWK18 afforded highly purified PEG-
peptides that controlled the PEG attachment site and
allowed comparison of reducible and nonreducible linkages.
Notably, the apparent binding affinity of both PEG-
peptides for DNA were equivalent to AlkCWK18 as deter-
mined by the intercalator exclusion assay (Figure 4),
Figure 9sIn vitro gene transfer efficiency of PEG-CWK18 DNA condensates. The in vitro expression of luciferase in HepG2 cells is compared for PEG-VS-CWK18
and PEG-SS-CWK18 as well as cocondensates prepared with AlkCWK18 at the ratios indicated. LipofectAce is included as a control gene transfer agent.
Figure 10sHepG2 cell binding of peptide DNA condensates. HepG2 cells
were transfected for 5 h with 45 nCi (10 µg) of 125I-DNA condensates prepared
with either AlkCWK18, PEG-VS-CWK18, or PEG-SS-CWK18. The cell associated
DNA recovered is expressed as the percent of 125I-DNA dosed onto cells.
The results represent the mean ± SD for three determinations.
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indicating that conjugates of CWK18 retain their ability to
bind and condense DNA. Due to the homogeneity of the
peptide portion of PEG-VS-CWK18 and PEG-SS-CWK18,
DNA condensates formed at charge ratios of 1.8:1 or higher
achieved a constant particle size and ú potential, establish-
ing both the absence of interfering peptides and that excess
PEG-peptide does not bind to fully condensed DNA.
ú potential measurements revealed evidence that PEG-
peptides altered the surface properties of DNA condensate.
The ú potential of PEG-VS-CWK18 and PEG-SS-CWK18
DNA condensates were indistinguishable and reached a
minimum of +10 mV at a calculated charge ratio of 1.8:1
(Figure 5B). The decrease in ú potential resulted from the
covalent attachment of PEG since the addition of equiva-
lent amounts of free PEG to AlkCWK18 DNA condensates
did not influence its ú potential (data not shown). Likewise,
analysis of DNA cocondensates established a correlation
between the ú potential and the mol % of PEG-VS-CWK18
incorporated into the cocondensate (Figure 6B). The re-
covery of the approximate input ratio of AlkCWK18 and
PEG-VS-CWK18 following prolonged dialysis confirmed the
formation of DNA cocondensates. This allowed add-mixing
of two condensing peptides (AlkCWK18 and PEG-VS-
CWK18) to systematically alter both physical and biological
properties of peptide DNA condensates.
The formation of a steric layer is highly dependent on
the amount PEG loaded onto DNA condensates.10,12 This
is most evident with DNA cocondensates possessing be-
tween 0 and 25 mol % PEG-peptide where the ú potential
decreased sharply to +20 mV and then only declined
gradually to reach +10 mV at 25-100 mol % PEG-peptide.
Even though the ú potential only changed by +10 mV when
titrating between 25 and 100 mol % of PEG-peptide (Figure
6B), these DNA condensates were most altered in solubility
and gene transfer efficiency.
The solubility achieved for 100 mol % PEG-peptide DNA
condensates (2 mg/mL) is far greater than the solubility
reported (60 µg/mL) for other PEG-peptides DNA conden-
sates.12 This physical property appears to be very depend-
ent on the loading density of PEG since cocondensates
prepared with 50 mol % PEG-VS-CWK18 were not improved
in solubility relative to AlkCWK18 DNA condensates. Even
cocondensates formed with as much as 90 mol % PEG-VS-
CWK18 demonstrated an increase in particle size at con-
centrations greater than 750 µg/mL, indicating that even
slightly less PEG on the DNA condensate will result in
lower solubility.
Earlier studies demonstrated that the in vitro gene
transfer efficiency for peptide DNA condensates was de-
pendent on the charge ratio.19,24 The expression reached a
maximum when AlkCWK18 DNA condensates were formed
at charge ratio of 1.8:1 or higher, suggesting that the
positive charge on DNA condensates contributes to their
spontaneous transfection in cell culture. In support of this
hypothesis, fully condensed PEG-VS-CWK18 DNA conden-
sates prepared at a charge ratio of 2.3:1 possess a lower ú
potential of +10 mV and reduced spontaneous gene trans-
fer by 1000-fold compared to AlkCWK18 DNA condensates.
Likewise, DNA cocondensates possessing intermediate ú
potential partially reduced gene transfer, further demon-
strating a correlation between DNA condensate charge and
the level of spontaneous gene transfer. However, these data
also established that the PEG load level needed to block
spontaneous gene transfer in vitro is much lower than that
required to create soluble PEG-peptide DNA condensates.
Even though PEG-VS-CWK18 and PEG-SS-CWK18 DNA
condensates were equivalent in their physical properties,
they proved to be unequivalent in their ability to reduce
spontaneous gene transfer (Figure 9). Since the two pep-
tides only differ in their linkage between PEG and peptide,
a possible explanation was the reduction of PEG-SS-CWK18
either outside or inside the cell to form CWK18 DNA
condensates during the time of transfection. To test this
hypothesis, radioiodinated DNA condensates were used to
determine the percent cell associated after a 5 h transfec-
tion (Figure 10). PEG-VS-CWK18 DNA condensates did not
significantly bind to cells, with only 0.2% of the dose being
cell associated. In contrast, 14% of AlkCWK18 DNA con-
densates and 6.8% of PEG-SS-CWK18 DNA condensates
dose were cell-associated following 5 h transfection, sup-
porting the hypothesis that differences in cell uptake are
responsible for the 2 orders of magnitude difference in gene
expression mediated by PEG-SS-CWK18 and PEG-VS-
CWK18 DNA condensates. To determine if PEG-SS-CWK18
underwent reduction during gene transfer, its stability was
analyzed while incubating in cell culture media containing
2% FCS. This led to its partial reduction over time (data
not shown), suggesting that the removal of PEG by disul-
fide bond scission results in the formation of CWK18 DNA
condensates in situ and is a likely explanation of the
difference between PEG-SS-CWK18 and PEG-VS-CWK18
DNA condensates.
Therefore, the utility of PEG-SS-CWK18 may be in
generating soluble DNA condensates that can be formu-
lated within a gene-activated matrix intended for implan-
tation in which targeting is not necessary and spontaneous
transfection of infiltrating cells is desired.25 Alternatively,
the greater stability of PEG-VS-CWK18 may result in its
utility in modifying the surface of DNA condensates used
during intravenous gene delivery.
Future studies will demonstrate the utility of PEG-
peptides in gene activated matrixes and in altering the
biodistribution of DNA condensates in vivo. The ability to
form DNA cocondensates that incorporate both PEG and
targeting ligands attached to CWK18 may provide a unique
approach to systematically optimize gene delivery formula-
tions for maximum efficacy in vivo.
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